THERAPEUTIC EFFECTS OF INTERLEUKIN-12 GENE in vivo VACCINE FOR MURINE T CELL LYMPHOMA (EL4) IN C57BL/6 MICE
- VernacularTitle:白细胞介-素12基因invivo疫苗治疗恶性淋巴瘤的实验研究
- Author:
Qianli JIANG
;
Wanming DA
;
Sha JIANG
- Publication Type:Journal Article
- Keywords:
lymphoma;
interleukin 12;
vaccines;
gene therapy
- From:
Medical Journal of Chinese People's Liberation Army
1983;0(05):-
- CountryChina
- Language:Chinese
-
Abstract:
C57BL/6 synergistical mice were divided into 4 groups (10 mice each). The first group was negative control without any interference. Each mouse in the other 3 groups was subcutaneously inoculated with 1 10 6 wide type (wt) EL4 tumor cells. Then each group was treated either with interleukin 12 (mIL 12) in vivo vaccine or NeoR control vaccine or PBS(positive control group) on day 1, 7, 14, 21, on the same place where wt EL4 tumor was inoculated. mIL 12 in vivo vaccine and NeoR control vaccine were package cells which can produce retrovirus (RV) with mIL 12 or NeoR gene, the vaccine was 60 Co irradiated and injected (1?10 7 cells/mouse). All mice in positive group and NeoR control group died of tumors in a month, while 5/10 mice in mIL 12 in vivo vaccine groups survived without tumors for more than 60 days. The 5 survived mice were rechallenged with 5?10 5 wt EL4 cells, 3/5 mice even survived without tumors for another 60 days. Among the mice with tumors in vivo vaccine group mice, compared with the controls, the development of tumors was delayed ( P
